Facile synthesis of ultrasmall PEGylated iron oxide nanoparticles for dual-contrast T1- and T2-weighted magnetic resonance imaging
- PMID: 21508500
- DOI: 10.1088/0957-4484/22/24/245604
Facile synthesis of ultrasmall PEGylated iron oxide nanoparticles for dual-contrast T1- and T2-weighted magnetic resonance imaging
Abstract
The development of new types of high-performance nanoparticulate MR contrast agents with either positive (T(1)) or dual-contrast (both positive and negative, T(1) + T(2)) ability is of great importance. Here we report a facile synthesis of ultrasmall PEGylated iron oxide nanoparticles for dual-contrast T(1)- and T(2)-weighted MRI. The produced superparamagnetic iron oxide nanoparticles (SPIONs) are of high crystallinity and size uniformity with an average diameter of 5.4 nm, and can be individually dispersed in the physiological buffer with high stability. The SPIONs reveal an impressive saturation magnetization of 94 emu g(-1) Fe(3)O(4), the highest r(1) of 19.7 mM(-1) s(-1) and the lowest r(2)/r(1) ratio of 2.0 at 1.5 T reported so far for PEGylated iron oxide nanoparticles. T(1)- and T(2)-weighted MR images showed that the SPIONs could not only improve surrounding water proton signals in the T(1)-weighted image, but induce significant signal reduction in the T(2)-weighted image. The good contrast effect of the SPIONs as T(1) + T(2) dual-contrast agents might be due to its high magnetization, optimal nanoparticle size for T(1) + T(2) dual-contrast agents, high size monodispersity and excellent colloidal stability. In vitro cell experiments showed that the SPIONs have little effect on HeLa cell viability.
Similar articles
-
Targeted dual-contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles.Biomaterials. 2011 Jul;32(20):4584-93. doi: 10.1016/j.biomaterials.2011.03.018. Epub 2011 Mar 31. Biomaterials. 2011. PMID: 21458063
-
Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T1 magnetic resonance imaging contrast agents.J Am Chem Soc. 2011 Aug 17;133(32):12624-31. doi: 10.1021/ja203340u. Epub 2011 Jul 25. J Am Chem Soc. 2011. PMID: 21744804
-
Hot-injection synthesis of iron/iron oxide core/shell nanoparticles for T2 contrast enhancement in magnetic resonance imaging.Chem Commun (Camb). 2011 Aug 28;47(32):9221-3. doi: 10.1039/c1cc13416g. Epub 2011 Jul 15. Chem Commun (Camb). 2011. PMID: 21761066
-
Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents.Chem Soc Rev. 2012 Apr 7;41(7):2575-89. doi: 10.1039/c1cs15248c. Epub 2011 Dec 2. Chem Soc Rev. 2012. PMID: 22138852 Review.
-
Magnetic iron oxide nanoparticles for biomedical applications.Future Med Chem. 2010 Mar;2(3):427-49. doi: 10.4155/fmc.09.164. Future Med Chem. 2010. PMID: 21426176 Review.
Cited by
-
Targeting T1 and T2 dual modality enhanced magnetic resonance imaging of tumor vascular endothelial cells based on peptides-conjugated manganese ferrite nanomicelles.Int J Nanomedicine. 2016 Aug 19;11:4051-63. doi: 10.2147/IJN.S104686. eCollection 2016. Int J Nanomedicine. 2016. PMID: 27578974 Free PMC article.
-
In situ embedding dual-Fe nanoparticles in synchronously generated carbon for the synergistic integration of magnetic resonance imaging and drug delivery.Nanoscale Adv. 2020 Sep 26;2(11):5296-5304. doi: 10.1039/d0na00714e. eCollection 2020 Nov 11. Nanoscale Adv. 2020. PMID: 36132027 Free PMC article.
-
D-Alpha-Tocopheryl Poly(ethylene Glycol 1000) Succinate-Coated Manganese-Zinc Ferrite Nanomaterials for a Dual-Mode Magnetic Resonance Imaging Contrast Agent and Hyperthermia Treatments.Pharmaceutics. 2022 May 6;14(5):1000. doi: 10.3390/pharmaceutics14051000. Pharmaceutics. 2022. PMID: 35631586 Free PMC article.
-
Magnetic Nanomaterials as Contrast Agents for MRI.Materials (Basel). 2020 Jun 5;13(11):2586. doi: 10.3390/ma13112586. Materials (Basel). 2020. PMID: 32517085 Free PMC article. Review.
-
Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications.Adv Drug Deliv Rev. 2019 Jan 1;138:302-325. doi: 10.1016/j.addr.2019.01.005. Epub 2019 Jan 11. Adv Drug Deliv Rev. 2019. PMID: 30639256 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical